Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
$0.22
$0.22
$0.22
$8.16
$1.70M0.691,500 shsN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$7.90
-4.6%
$8.39
$5.01
$10.75
$10.11M0.88175,210 shs7,546 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
$0.12
$0.07
$1.42
$2.79M1.973.40 million shs916,801 shs
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
$0.98
$1.66
$0.60
$3.00
$31.43M-6.03143 shsN/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
+0.62%+2.80%-11.22%+53.71%+35.40%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+3.68%-3.43%-44.20%-50.84%+7,599,900.00%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
+58.05%+58.05%-55.86%-21.61%-2.01%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
N/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
2.00
HoldN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/A
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest GHSI, NBY, VICP, PXSLY, and ASPCF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/2/2024
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
$2.12M0.80N/AN/A($3.38) per share-0.07
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.83$0.14 per share57.50$6.39 per share1.24
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.19N/AN/A$0.12 per share0.64
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
N/AN/AN/AN/A($0.03) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
-$33.82M-$3.57N/AN/A-924.33%N/A-74.62%N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$0.1171.82N/A0.51%2.01%1.21%5/20/2024 (Estimated)
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.10N/A-65.46%-150.14%-53.48%N/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
-$990KN/A0.00N/AN/AN/A-598.80%N/A

Latest GHSI, NBY, VICP, PXSLY, and ASPCF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A$0.33+$0.33$0.33N/A$21.56 million
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
N/A
0.67
0.34
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
9.01
6.98
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
N/A
0.13
0.13

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acerus Pharmaceuticals Co. stock logo
ASPCF
Acerus Pharmaceuticals
147.71 millionN/ANot Optionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
91.28 million1.27 millionNot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable
Vicapsys Life Sciences, Inc. stock logo
VICP
Vicapsys Life Sciences
232.07 million30.15 millionNot Optionable

GHSI, NBY, VICP, PXSLY, and ASPCF Headlines

SourceHeadline
Scanning Electron Microscopy for the Life SciencesScanning Electron Microscopy for the Life Sciences
cambridge.org - April 20 at 9:36 AM
Vicapsys Life Sciences (OTCMKTS:VICP) Trading Down 36.1%Vicapsys Life Sciences (OTCMKTS:VICP) Trading Down 36.1%
americanbankingnews.com - April 18 at 1:34 AM
EY Life SciencesEY Life Sciences
pmlive.com - April 8 at 1:51 PM
Life ScienceLife Science
dmagazine.com - January 30 at 8:57 AM
Caris Life SciencesCaris Life Sciences
dmagazine.com - November 30 at 3:41 PM
Anavex Life Sciences Corp AVXLAnavex Life Sciences Corp AVXL
morningstar.com - November 4 at 11:28 PM
VICP - Vicapsys Life Sciences, Inc.VICP - Vicapsys Life Sciences, Inc.
finance.yahoo.com - August 9 at 4:25 PM
ViCapsys files for Nasdaq uplisting, $8M public offeringViCapsys files for Nasdaq uplisting, $8M public offering
msn.com - July 3 at 3:00 PM
Life sciences sector to get £650m boost in new Government funding packageLife sciences sector to get £650m boost in new Government funding package
aol.co.uk - June 9 at 8:18 PM
‘Not Seeing Any Activity At All’: Once-Hot Life Sciences Leasing Market Freezes‘Not Seeing Any Activity At All’: Once-Hot Life Sciences Leasing Market Freezes
bisnow.com - April 1 at 1:05 PM
The Science of LifeThe Science of Life
nature.com - March 29 at 10:46 AM
The ultimate list of leaders in life sciences.The ultimate list of leaders in life sciences.
statnews.com - March 16 at 7:27 AM
Defining life and personhood: What science, philosophy, and religion have to sayDefining life and personhood: What science, philosophy, and religion have to say
kcrw.com - March 13 at 10:54 AM
Life Sciences Innovator Category Winner 2023Life Sciences Innovator Category Winner 2023
news-medical.net - February 23 at 7:19 AM
Global law firm Goodwin is setting up a Philly tech, startups and life sciences practiceGlobal law firm Goodwin is setting up a Philly tech, startups and life sciences practice
technical.ly - February 21 at 12:23 AM
Global Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market ProspectsGlobal Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market Prospects
benzinga.com - February 19 at 11:43 PM
Focused exclusively on life sciences, three top investors set out on their ownFocused exclusively on life sciences, three top investors set out on their own
statnews.com - January 28 at 2:12 AM
Top risks for life sciences sector revealed – reportTop risks for life sciences sector revealed – report
canadianlawyermag.com - January 15 at 1:36 PM
Houston On Track As Future Life Sciences Powerhouse, But Everyone Needs To Mind The Gaps FirstHouston On Track As Future Life Sciences Powerhouse, But Everyone Needs To Mind The Gaps First
bisnow.com - January 15 at 1:36 PM
$1.6B Life Sciences Hub Backed By Hochul, Adams Coming To Kips Bay$1.6B Life Sciences Hub Backed By Hochul, Adams Coming To Kips Bay
bisnow.com - October 16 at 10:15 PM
ViCapsys Life Sciences Appoints Three New Board MembersViCapsys Life Sciences Appoints Three New Board Members
finance.yahoo.com - September 29 at 6:41 PM
ViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive OfficerViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive Officer
finance.yahoo.com - April 18 at 12:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acerus Pharmaceuticals logo

Acerus Pharmaceuticals

OTCMKTS:ASPCF
Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.
Guardion Health Sciences logo

Guardion Health Sciences

NASDAQ:GHSI
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Pharmaxis logo

Pharmaxis

OTCMKTS:PXSLY
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Vicapsys Life Sciences logo

Vicapsys Life Sciences

OTCMKTS:VICP
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Cumming, Georgia.